# Trial of Taselisib in Overgrowth

> **NCT03290092** · PHASE1,PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 19 (actual)

## Conditions studied

- PIK3CA-Related Overgrowth

## Interventions

- **DRUG:** Taselisib (GDC0032)
- **DRUG:** Taselisib (GDC0032)

## Key facts

- **NCT ID:** NCT03290092
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-31
- **Primary completion:** 2019-02-14
- **Final completion:** 2019-11-04
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** In accordance with the protocol, following the occurrence of two SUSARs, the TOTEM trial was stopped early for safety reasons.
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290092, "Trial of Taselisib in Overgrowth". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03290092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*